CA-INGRAM-MICRO
13.3.2019 18:02:11 CET | Business Wire | Press release
INGRAM MICRO CLOUD SUMMIT – Ingram Micro Inc. today announced the next iteration of the Ingram Micro Cloud Marketplace, adding new features, functionality and resources designed to help technology partners and independent software vendors (ISVs) to do more with more. Inspired by partner feedback, the new enhancements streamline and standardize processes, increase efficiencies and effectiveness in sales and marketing, and ultimately will make it easier for technology partners and ISVs to grow their business more profitably using the Ingram Micro Cloud Marketplace.
Among the key enhancements and features readily available today as part of the Ingram Micro Cloud Marketplace are:
Ingram Micro Connect – Powered by CloudBlue, Ingram Micro Connect is an easy-to-use, digital module that provides a fast and cost-effective way to publish, manage and promote cloud services to as many as 200,000 technology partners using Ingram Micro Cloud Marketplace. Ingram Micro Connect simplifies and automates distribution by providing robust publishing tools, digital contracting, multi-marketplace targeting, and sales and marketing content creation tools.
New Customer Experience – A new, modern UI for the Ingram Micro Cloud Marketplace featuring an updated, user-friendly interface that makes it easier for technology partners to find, navigate, and purchase cloud services while streamlining end-customer management.
Sales & Marketing Hub – An industry-first, digital suite for technology partners designed to help educate and enable their salespeople on cloud services while providing pre-built campaign templates and valuable marketing tools to their marketers. The complementary resource provides a single destination to discover and learn about cloud services, create and execute marketing campaigns, and customize sales enablement and access industry insights so they can be the go-to cloud experts for their customers.
Marketplace API – A new API that enables technology partners to quickly integrate their own online storefront, CRM and billing systems into the Ingram Micro Cloud Marketplace. As a result, technology partners using the Cloud Marketplace can now better manage and automate ordering and billing; create and manage customer accounts, users and subscriptions; and retrieve billing data that can be used to bill end customers.
“Ingram Micro has elevated the experience our technology partners and ISVs are having with the Ingram Micro Cloud Marketplace, enabling them simply to do more with more and capitalize on the growing opportunity cloud continues to deliver,” said Tarik Faouzi, Vice President of Cloud Product Management, Ingram Micro. “These enhancements, powered by CloudBlue, all tie to Ingram Micro’s overall vision to provide our partners a hyper-scale digital platform, access to an infinite ecosystem, and proven go-to-market services.”
Ingram Micro’s Cloud Marketplace was first to market in 2009, and is now used by more than 55,000 technology partners worldwide to manage nearly four million fully-automated seats. The Ingram Micro Cloud Marketplace can be found here .
Supporting Partner Quotes and Industry Statistics
“Using Ingram Micro Connect, we’re able to quickly add our cloud
products to the Cloud Marketplace and position them in front of Ingram
Micro’s thousands of resellers with uniform, ready-to-use sales and
marketing resources.”
- Dmitry Leonov, Co-Founder, SaneBox
Channel partners spend up to 40 percent of their time sifting through
content.
- Source: Quotient, “Five Step Guide to Enable Channel
Sale,” May 2016
When enabled, resellers achieve 28 percent shorter sales cycles and a 12
percent higher lead conversion rate.
- Source: Aberdeen Group,
“Territory, Training, Technology: Best-in-Class Channel Sales
Management,” March 2016
A recent study from The 2112 Group notes 73% of MSPs don’t have
marketing plans or programs; 52% of partners say they’re expanding sales
and marketing efforts of existing products and services to grow their
business in 2019.
- Source: The 2112 Group, “2017 State of the
U.S. Cloud Channel Report”
“The Sales & Marketing Hub helps significantly reduce the time it takes
us to learn about vendor products and create the sales and marketing
assets that go along with them. Plus, we now have access to a library of
research on cloud business strategies and industry news that will help
us develop more effective strategies for our cloud business. GetBEE
looks forward to growing on the Sales & Marketing Hub with Ingram Micro.”
-
Thea Myhrvold, Founder and CEO, GetBEE
“Together, these new additions to the Cloud Marketplace will enable our
technology vendor partners to automate more processes and, as a result,
not only operate more efficiently to increase profits, but also to
expand their market footprint, and enable our reseller partners to
monetize an ever larger pool of anything as a service.”
- David
Wippich, CTO and Senior Vice President, Global Cloud, Ingram Micro
About Ingram Micro Cloud
At Ingram Micro Cloud,™ we view cloud not just as a single technology, but as a foundational platform to run and drive a whole new way of doing business. By leveraging our platforms and ecosystem, cloud service providers, telecom companies, resellers and enterprises can quickly transform and get up and running in the cloud within minutes, with little to no investment. Our portfolio includes vetted security, communication and collaboration, business applications, cloud management services and infrastructure solutions designed to help clients monetize and manage the entire lifecycle of cloud and digital services, infrastructure and IoT subscriptions. For more information, please visit: www.IngramMicroCloud.com .
About Ingram Micro Inc.
Ingram Micro helps businesses Realize the Promise of Technology ™. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. More at www.ingrammicro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005555/en/
Contact:
Global Media Contact: Marie Rourke WhiteFox Marketing Inc. (for CloudBlue and Ingram Micro) 714-292-2199 marie@whitefoxpr.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom